"In a traditional corneal transplant, the central part of the cornea is removed and a donor cornea is sutured in its place. Image courtesy of Dr. Edward Holland, University of Cincinnati.
Ten years after a transplant, a cornea fro"...
Lumigan Patient Information Including Side Effects
Brand Names: Lumigan
Generic Name: bimatoprost ophthalmic (Pronunciation: bih MAT o prost)
- What is bimatoprost ophthalmic (Lumigan)?
- What are the possible side effects of bimatoprost ophthalmic (Lumigan)?
- What is the most important information I should know about bimatoprost ophthalmic (Lumigan)?
- What should I discuss with my health care provider before using bimatoprost ophthalmic (Lumigan)?
- How should I use bimatoprost ophthalmic (Lumigan)?
- What happens if I miss a dose (Lumigan)?
- What happens if I overdose (Lumigan)?
- What should I avoid while using bimatoprost ophthalmic (Lumigan)?
- What other drugs will affect bimatoprost ophthalmic (Lumigan)?
- Where can I get more information?
What is bimatoprost ophthalmic (Lumigan)?
Bimatoprost ophthalmic reduces pressure in the eye by increasing the amount of fluid that drains from the eye.
Bimatoprost ophthalmic is used to treat certain types of glaucoma and other causes of high pressure inside the eye. Bimatoprost is also used to improve fullness, length, and color of the eyelashes in people with a condition called hypotrichosis (HYE-poe-trye-KOE-sis), a lack of eyelash growth.
Bimatoprost ophthalmic may also be used for other purposes not listed in this medication guide.
What are the possible side effects of bimatoprost ophthalmic (Lumigan)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using bimatoprost ophthalmic and call your doctor at once if you have any of these serious side effects:
- redness, swelling, itching, or pain in or around your eye;
- oozing or discharge from your eye;
- increased sensitivity to light;
- vision changes.
Less serious side effects may include:
- mild eye discomfort;
- feeling like something is in your eye;
- dry or watery eyes; or
- stinging or burning of the eyes after using the drops.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the Lumigan (bimatoprost ophthalmic solution 0.03% for glaucoma) Side Effects Center for a complete guide to possible side effects
What is the most important information I should know about bimatoprost ophthalmic (Lumigan)?
Do not use this medication while you are wearing contact lenses. This medication may contain a preservative that can be absorbed by soft contact lenses. Wait at least 15 minutes after using bimatoprost before putting your contact lenses in.
Bimatoprost ophthalmic may cause a gradual change in the color of your eyes or eyelids and lashes, as well as increased growth or thickness of your eyelashes. These color changes, usually an increase in brown pigment, occur slowly and you may not notice them for months or years. Color changes may be permanent even after your treatment ends, and may occur only in the eye being treated. This could result in a cosmetic difference in eye or eyelash color from one eye to the other.
Do not allow the dropper to touch any surface, including the eyes or hands. If the dropper becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye.
After using this medication, wait at least 5 minutes before using any other eye drops that your doctor has prescribed.
Additional Lumigan Information
- Lumigan Drug Interactions Center: bimatoprost opht
- Lumigan Side Effects Center
- Lumigan Overview including Precautions
- Lumigan FDA Approved Prescribing Information including Dosage
Lumigan - User Reviews
Lumigan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get breaking medical news.